Vetr Upgrades Valeant

The Vetr crowd downgraded Valeant Pharmaceuticals International, Inc. (NASDAQ: VRX) from 4 stars to 4.5 stars.

The crowd rates Valeant a Buy with a price target of $19.72. Wall Street analysts price the stock's value at $24.58.

See how crowdsourced ratings can help predict the market?

Valeant shares were trading up slightly at $17.75 after Tuesday's close.

For the crowd's full analysis of the stock, click here.